Background
Ovarian cancer is a heterogenous malignancy with multiple histological subtypes. The most common form of ovarian cancer is epithelial ovarian cancer, of which the serous subtype is most common. The second most common, accounting for approximately 10% of epithelial ovarian cancers, is endometrioid carcinoma [1]. As a result of the rare nature of ovarian endometrioid carcinoma, research and understanding of this subtype, its presentation, management, and prognosis, are limited. Cytoreductive surgery remains the mainstay treatment for this subtype of ovarian cancer, and the extent of tumour resection has been suggested to be a major prognostic factor [2-4].
Here we present the case of a woman in her late 40’s with pelvic recurrence of endometrioid ovarian cancer. The patient has consented for this case report to be written and published. The initial histopathology report graded the tumour as grade 1, without any evidence of clear cells, an indicator of aggressiveness. The cancer was International Federation of Gynecology and Obstetrics (FIGO) stage IC2, restricted to the ovaries and on a background of atypical endometriosis. This case highlights the surgical complexity of optimal cytoreductive surgery in recurrent endometrioid ovarian cancer, best achieved by a multidisciplinary approach.